6.28

2.48% -0.16

After Hours: 6.25 -0.03 -0.48%

Polaryx Therapeutics Inc (PLYX)

Overview News Price History Discussions Forecast

Polaryx Therapeutics Inc stock is traded at $6.28, with a volume of 232.03K. It is down -2.48% in the last 24 hours and up +126.71% over the past month. Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small molecule drug candidates designed to address core pathological mechanisms common to LSDs.

Previous Close:

$6.44

Open:

$6.23

24h Volume:

232.03K

Relative Volume:

0.15

Market Cap:

$297.32M

Revenue:

Net Income/Loss:

$-8.99M

P/E Ratio:

-33.09

EPS:

-0.1898

Net Cash Flow:

$-3.94M

1W Performance:

+13.56%

1M Performance:

+126.71%

6M Performance:

+0.00%

1Y Performance:

+0.00%

1-Day Range:

$6.23

$6.90

1-Week Range:

$5.11

$6.90

52-Week Range:

$2.201

$33.90

Polaryx Therapeutics Inc Stock (PLYX) Company Profile

Name

Polaryx Therapeutics Inc

Sector

Healthcare (1114)

Industry

Biotechnology (623)

Phone

201-940-7236

Address

140 EAST RIDGEWOOD AVENUE, PARAMUS

Employee

Twitter

Next Earnings Date

Latest SEC Filings

PLYX's Discussions on Twitter

Compare PLYX vs VRTX, REGN, ALNY, ARGX, INSM

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PLYX Polaryx Therapeutics Inc	6.28	304.89M	0	-8.99M	-3.94M	-0.1898
VRTX Vertex Pharmaceuticals Inc	454.97	113.96B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	749.47	78.41B	14.34B	4.50B	3.77B	41.56
ALNY Alnylam Pharmaceuticals Inc	328.70	40.85B	3.71B	313.75M	465.38M	2.2571
ARGX Argen X Se Adr	697.05	42.05B	4.16B	1.29B	734.26M	19.58
INSM Insmed Inc	148.31	29.99B	606.42M	-1.28B	-997.58M	-6.403

Polaryx Therapeutics Inc Stock (PLYX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-27-26	Initiated	Maxim Group	Buy

Polaryx Therapeutics Inc Stock (PLYX) Latest News

Mar 25, 2026

Harmony Biosciences stock faces pipeline scrutiny amid Polaryx integration challenges and rare disea - AD HOC NEWS

Mar 25, 2026

Mar 24, 2026

Polaryx Therapeutics: Advancing Innovative Therapies for Rare Pediatric Lysosomal Storage Disorders (LSDs) - Minichart

Mar 24, 2026

Polaryx Therapeutics (NASDAQ: PLYX) outlines rare pediatric LSD pipeline - Stock Titan

Mar 24, 2026

PLYX: Net loss improved to $9.0M in 2025, but cash only funds operations through Q3 2026 - TradingView

Mar 24, 2026

Mar 22, 2026

Polaryx Therapeutics, Inc.(NasdaqCM: PLYX) added to S&P TMI Index - marketscreener.com

Mar 22, 2026

Mar 19, 2026

Polaryx Therapeutics (PLYX) Stock Trends and Sentiment 2026 - MarketBeat

Mar 19, 2026

PLYX: Polaryx Therapeutics, Inc.Comparative Chart - Zacks Investment Research

Mar 19, 2026

Mar 18, 2026

FDA grants fast track status to Polaryx’s PLX-200 for CLN2 disease By Investing.com - Investing.com South Africa

Mar 18, 2026

Mar 17, 2026

Polaryx Therapeutics (PLYX) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat

Mar 17, 2026

Polaryx’s PLX-200 granted FDA Fast Track Designation in LINCL/CLN2 - TipRanks

Mar 17, 2026

FDA grants fast track status to Polaryx’s PLX-200 for CLN2 disease - Investing.com

Mar 17, 2026

Polaryx Therapeutics Says FDA Grants Fast Track Status to PLX-200 - marketscreener.com

Mar 17, 2026

Polaryx Therapeutics Receives FDA Fast Track Designation for PLX‑200 for Late‑Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease) - The Manila Times

Mar 17, 2026

Polaryx Therapeutics Stock Rises Amidst Key Clinical Trials Development - timothysykes.com

Mar 15, 2026

symbol__ Stock Quote Price and Forecast - CNN

Mar 15, 2026

Mar 14, 2026

Top Polaryx Therapeutics (PLYX) Competitors 2026 - MarketBeat

Mar 14, 2026

Polaryx Therapeutics Stock Surges With New Phase Trial Decision - StocksToTrade

Mar 14, 2026

Mar 12, 2026

PLYX Stock Rockets To Best Day Ever: Why Retail Traders Are Piling Into This Battered Biotech - Stocktwits

Mar 12, 2026

Polaryx Therapeutics Deepens Engagement with the Krabbe Disease Community Through Scientific and Patient Advocacy Events - Bitget

Mar 12, 2026

Biotech backs Krabbe families with research summit and Putt-Putt event - Stock Titan

Mar 12, 2026

Mar 11, 2026

Battered Polaryx Stock Turns Retail-Trader Heads After 70% Surge: What’s Behind The Sudden Interest? - Asianet Newsable

Mar 11, 2026

Polaryx Therapeutics, Inc.Common Stock (NQ: PLYX - The Chronicle-Journal

Mar 11, 2026

Mar 10, 2026

Polaryx Therapeutics (PLYX) Insider Trading Activity 2026 - MarketBeat

Mar 10, 2026

Mar 06, 2026

PLYX Forecast, Price Target & Analyst Ratings | POLARYX THERAPEUTICS INC (NASDAQ:PLYX) - ChartMill

Mar 06, 2026

Mar 01, 2026

Polaryx Therapeutics, Inc.: Target Price Consensus and Analysts Recommendations | PLYX | US73110F1003 - marketscreener.com

Mar 01, 2026

Feb 27, 2026

Polaryx commits to patients with rare pediatric lysosomal storage disorders - TipRanks

Feb 27, 2026